Home / Health / Covid-19: CSIR gets nod for phase III trials of antiviral drug Umifenovir

Covid-19: CSIR gets nod for phase III trials of antiviral drug Umifenovir

Umifenovir is mainly used for treatment of influenza and is available in China and Russia, and has recently come into prominence due to its potential use for Covid19 patients

hospital, beds, patients, doctors, nurses, health care, health workers, coronavirus, testing, vaccine

Premium

This drug has a good safety profile and acts by preventing entry of virus into human cells and also by priming the immune system, Ministry of Science and Technology said I'm a statement.

IANS

2 min read Last Updated : Jun 19 2020 | 1:21 PM IST

Amid the race to find a cure for the deadly coronavirus infection, Council of Scientific and Industrial Research (CSIR)-constituent lab CSIR-Central Drug Research Institute (CDRI) in Lucknow has received permission to carry out Phase III trial of antiviral drug Umifenovir.

Umifenovir is mainly used for treatment of influenza and is available in China and Russia, and has recently come into prominence due to its potential use for Covid19 patients.

Announcing the commencement of trial, Union Health Minister Harsh Vardhan said: "CSIR's constituent lab CSIR-Central Drug Research Institute (CDRI) Lucknow, has received permission for carrying out Phase III randomised, Double-blind, Placebo-controlled trial of

Topics : Coronavirus Coronavirus Vaccine CSIR

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in